

Vickie A Marshall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4344036/publications.pdf>

Version: 2024-02-01

28
papers

776
citations

516710

16
h-index

526287

27
g-index

29
all docs

29
docs citations

29
times ranked

888
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS). <i>Clinical Infectious Diseases</i> , 2016, 62, 730-738.	5.8	135
2	Conservation of Virally Encoded MicroRNAs in Kaposi Sarcoma-associated Herpesvirus in Primary Effusion Lymphoma Cell Lines and in Patients with Kaposi Sarcoma or Multicentric Castlemans Disease. <i>Journal of Infectious Diseases</i> , 2007, 195, 645-659.	4.0	95
3	Genotypic characterization of Kaposi's sarcoma-associated herpesvirus in asymptomatic infected subjects from isolated populations. <i>Journal of General Virology</i> , 2004, 85, 155-163.	2.9	78
4	Heterogeneity and Breadth of Host Antibody Response to KSHV Infection Demonstrated by Systematic Analysis of the KSHV Proteome. <i>PLoS Pathogens</i> , 2014, 10, e1004046.	4.7	57
5	Characteristics and outcomes of KSHV-associated multicentric Castlemans disease with or without other KSHV diseases. <i>Blood Advances</i> , 2021, 5, 1660-1670.	5.2	35
6	Sequence Analysis of Kaposi Sarcoma-associated Herpesvirus (KSHV) MicroRNAs in Patients with Multicentric Castlemans Disease and KSHV-Associated Inflammatory Cytokine Syndrome. <i>Journal of Infectious Diseases</i> , 2012, 205, 1665-1676.	4.0	33
7	Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castlemans disease. <i>Blood</i> , 2020, 135, 2316-2319.	1.4	33
8	Signatures of oral microbiome in HIV-infected individuals with oral Kaposi's sarcoma and cell-associated KSHV DNA. <i>PLoS Pathogens</i> , 2020, 16, e1008114.	4.7	31
9	Mutual detection of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in blood and saliva of Cameroonians with and without Kaposi's sarcoma. <i>International Journal of Cancer</i> , 2019, 145, 2468-2477.	5.1	30
10	Kaposi Sarcoma (KS)-Associated Herpesvirus MicroRNA Sequence Analysis and KS Risk in a European AIDS-KS Case Control Study. <i>Journal of Infectious Diseases</i> , 2010, 202, 1126-1135.	4.0	26
11	Genome-Wide Sequence Analysis of Kaposi Sarcoma-Associated Herpesvirus Shows Diversification Driven by Recombination. <i>Journal of Infectious Diseases</i> , 2018, 218, 1700-1710.	4.0	25
12	Distinct genetic architectures and environmental factors associate with host response to the β 2-herpesvirus infections. <i>Nature Communications</i> , 2020, 11, 3849.	12.8	24
13	Kaposi's Sarcoma-Associated Herpesvirus MicroRNA Single-Nucleotide Polymorphisms Identified in Clinical Samples Can Affect MicroRNA Processing, Level of Expression, and Silencing Activity. <i>Journal of Virology</i> , 2013, 87, 12237-12248.	3.4	22
14	Determinants of Gammaherpesvirus Shedding in Saliva Among Ugandan Children and Their Mothers. <i>Journal of Infectious Diseases</i> , 2018, 218, 892-900.	4.0	21
15	A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. <i>Oncologist</i> , 2017, 22, 505-e49.	3.7	20
16	Risk Factors for Kaposi's Sarcoma-associated Herpesvirus DNA in Blood and in Saliva in Rural Uganda. <i>Clinical Infectious Diseases</i> , 2020, 71, 1055-1062.	5.8	19
17	Plasma magnesium is inversely associated with Epstein-Barr virus load in peripheral blood and Burkitt lymphoma in Uganda. <i>Cancer Epidemiology</i> , 2018, 52, 70-74.	1.9	17
18	Sensitivity of the C-Terminal Nuclease Domain of Kaposi's Sarcoma-Associated Herpesvirus ORF29 to Two Classes of Active-Site Ligands. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	13

#	ARTICLE	IF	CITATIONS
19	Kaposi's sarcoma-associated herpesvirus T cell responses in HIV seronegative individuals from rural Uganda. <i>Nature Communications</i> , 2021, 12, 7323.	12.8	13
20	The Contribution of Kaposi's Sarcoma-Associated Herpesvirus to Mortality in Hospitalized Human Immunodeficiency Virus-Infected Patients Being Investigated for Tuberculosis in South Africa. <i>Journal of Infectious Diseases</i> , 2019, 220, 841-851.	4.0	11
21	Gammaherpesvirus infection and malignant disease in rhesus macaques experimentally infected with SIV or SHIV. <i>PLoS Pathogens</i> , 2018, 14, e1007130.	4.7	10
22	Relationship between human leukocyte antigen alleles and risk of Kaposi's sarcoma in Cameroon. <i>Genes and Immunity</i> , 2019, 20, 684-689.	4.1	10
23	Dual infection and recombination of Kaposi sarcoma herpesvirus revealed by whole-genome sequence analysis of effusion samples. <i>Virus Evolution</i> , 2020, 6, veaa047.	4.9	5
24	Everolimus-Induced Remission of Classic Kaposi's Sarcoma Secondary to Cryptic Splicing Mediated CTLA4 Haploinsufficiency. <i>Journal of Clinical Immunology</i> , 2020, 40, 774-779.	3.8	5
25	Polymorphisms in KSHV-encoded microRNA sequences affect levels of mature viral microRNA in Kaposi Sarcoma lesions. <i>Oncotarget</i> , 2018, 9, 35856-35869.	1.8	5
26	Epstein-Barr virus load is higher in long-term Hodgkin lymphoma survivors compared to their unaffected twins and unrelated controls. <i>British Journal of Haematology</i> , 2019, 185, 377-380.	2.5	1
27	Systematic Analysis of Kaposi's Sarcoma-Associated Herpesvirus Genomes from a Kaposi's Sarcoma (KS) Case-Control Study in Cameroon: Evidence of Dual Infections but No Association Between Viral Sequence Variation and KS Risk. <i>International Journal of Cancer</i> , 0, , .	5.1	1
28	IL-13 Expression Characterizes Effusions Associated with Primary Effusion Lymphoma but Not Other Disorders Caused By Kaposi Sarcoma Herpesvirus (KSHV). <i>Blood</i> , 2018, 132, 4137-4137.	1.4	0